Issue 3: May 2018   Save the Date ICRN Meeting Friday, June 1 6:30-7:30pm McCormick Center, Chicago Conquer Cancer Foundation Meeting Room S403A Click here to RSVP Updates from the 2nd Asia-Pacific Conference The conference was held on March 23 and 24, 2018 in collaboration with Siriraj University Hospital, Bangkok, Thailand. Approximately, 300 attendees from Thailand, China, South Korea and nearby Asian countries attended the conference. apcurecc.com The ICRN Executive Committee had several one day parallel meetings with our Asian collaborators to discuss areas of future collaboration. March 22, 2018 Meeting with collaborators from Pusan National University Hospital, South Korea Proposed projects: Immune profiling study comparing Asian versus U.S. cholangiocarcinoma patients Collaborate with the ICRN Translational Working Group to study the mRNA cholangiocarcinoma profiling Organize multi-institutional clinical trials March 22, 2018 Meeting with collaborators from Chiang Mai Hospital, Thailand Proposed projects: Study circulating DNA and cell-free DNA in hilar cholangiocarcinoma Genomic profiling of hilar cholangiocarcinoma Coordinate clinical trials studying liver transplantation for cholangiocarcinoma Plan collaborative epidemiological studies March 25, 2018 Meeting with collaborators from Second Military Hospital and Fudan University, Shanghai, China Proposed projects: Genomic profiling study comparing Chinese versus U.S. cholangiocarcinoma patients Organize multi-institutional clinical trials including neoadjuvant trials for cholangiocarcinoma ICRN Participating Centers U.S. Centers Christie NHS Foundation Trust Cleveland Clinic Foundation Emory University Fred Hutchinson Cancer Research Center Johns Hopkins University Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Moffitt Cancer Center University of California, San Francisco University of Michigan University of Southern California University of Utah University of Washington Vanderbilt University Virginia Mason Medical Center International Centers Chulalongkorn University [Thailand] Hacettepe University cancer Institute [Turkey] Hepatobiliary Medical Society Returned Scholar Association [China] National Health Research Institutes, Kaoshsiung Medicine University [Taiwan] Peking Union Medical College Hospital [China] Princess Margaret Hospital [Canada] Siriraj Hospital [Thailand] University of Calgary [Canada] University College of London Hospital [UK] University of Amsterdam [Netherlands] We would like to welcome our newest ICRN participating centers Banner Health, Arizona Eastern Hepatobiliary Surgery Hospital [China] Hannover Medical School [Germany] Institut Gustav Roussy [Paris] National Cancer Institute Hospital [Japan] Oregon Health and Sciences University Hospital Pusan National University Hospital [South Korea] Seoul National University College of Medicine [South Korea] The University of Arizona Cancer Center The University of Nottingham [London] Trinity College Dublin [Ireland] University Hospitals Cleveland Medical Center University of Miami University of Tennessee Health Science Center - Baptist Memorial Medical Group Yale University We would like to welcome our newest ICRN Executive Committee Members Dr. Li-Tzong Chen MD, PhD. He is Director of the National Institute of Cancer Research, National Health Research Institutes, Taiwan, where he is a Distinguished Investigator and Adjunct Attending Physician. Dr. Chen’s academic positions include Adjunct Professor at Kaohsiung Medical University and Taipei Medical University; Attending Physician at Division of Gastroenterology at Kaohsiung Medical University Hospital; and Attending Physician in the Department of Internal Medicine, National Cheng-Kung University Hospital, Taiwan. Dr. Chen is Chair of the Division of Hematology and Immunology, Minister of Sciences and Technology (MOST); and the Institution Review Board, and Protocol Review Committee of the Taiwan Cooperative Oncology Group, National Health Research Institutes. Dr. Haitao Zhao, MD, PhD. He is an Associate Professor and Associate Chief Physician at the Department of Liver Surgery at Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. Dr. Zhao has received several funds from the Ministry of Health and awards from Beijing Municipal Government. His research interests include benign/malignant tumors in the hepatobiliary system, intrahepatic and extrahepatic cholangiocarcinoma. Working Groups We welcome your participation in the Working Groups of your choice. Contact Dr. Reham Abdel-Wahab at raali@mdanderson.org for more information. Biorepository Working Group Coordinates the ICRN tissue and blood banking repository. Chair, Lewis Roberts, Mayo Clinic Co-Chair, TBA Genomics and Database Working Group Initiates genomic research projects, red cap database for clinical research. Chair, Lipika Goyal, MGH Co-Chair, Laura Goff, Vanderbilt University Immuno-Oncology Working Group Coordinates IO trials, study immune biomarker expression in cholangiocarcinoma. Chair, Nilo Azad, Johns Hopkins Co-Chair, Katie Kelley, UCSF Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center Madappa Kundranda, Banner Health Kabir Mody, Mayo Clinic Rachna Shroff, University of Arizona Radiation Oncology Working Group Increases utilization of radiation for treating cholangiocarcinoma patients in Asia and Europe, radiotherapy clinical trials, retrospective studies. Chair, Eugene Koay, MD Anderson Cancer Center Co-Chair, Randa Tao, University of Utah Surgical Working Group Spearheads efforts in surgical research, liver transplantation for cholangiocarcinoma patients and international surgical trials. Chair, Flavio Rocha, Virginia Mason University Co-Chair, Shishir Maithel, Emory University Yun Shin Chun, MD Anderson Cancer Center Translational Working Group Studies and implements translational initiatives. Chair, Supriya Saha, Fred Hutchinson Cancer Research Center Co-Chair, Larry Kwong, MD Anderson Cancer Center Working Group Updates Confidentiality Agreements have been executed with the Academic and Community Cancer Research United (ACCRU) and the PrECOG. 3 clinical trials have been approved by sponsors but not yet activated. Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for locally advanced intrahepatic cholangiocarcinoma Study PIs: Flavio G. Rocha and Shishir Maithel Study Objective: Primary endpoint is to assess the feasibility of this regimen in the preoperative setting. Secondary endpoints include resectability rate, response to chemotherapy, hepatic and extrahepatic recurrence free survival, R0 resection rates, lymph node positivity, postoperative complications, and overall survival. Sponsors: PrECOG, Celgene Olaparib for Cholangiocarcinoma Patients with DNA Repair Genes Defects Study PIs: Tanios Bekaii-Saab and Daniel Ahn Study Objective: Primary endpoint is to assess tumor response rate. Secondary endpoints include progression free survival and overall survival. Sponsors: ACCRU, AstraZeneca First Line Trial of Gemcitabine and Cisplatin with AG120 or INCB054828 for Advanced Cholangiocarcinoma Study PIs: Jonathan Whisenant and Ghassan Abou-Alfa Study Objective: Primary endpoint is to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, pharmacodynamics and the preliminary efficacy and clinical activity. Secondary endpoints are to evaluate progression free survival and overall survival and measure plasma 2-hydroxglutarate (2-HG) levels at baseline and after multiple doses of AG-120 study Sponsors: ACCRU, Incyte, Agios Other data sharing projects: Molecular profiling of surgically resected cholangiocarcinoma Liquid biopsies to determine risk of recurrence and survival for resected cholangiocarcinoma: a potential strategy to guide adjuvant therapy Cholangiocarcinoma immune profiling in Western and Asian populations Contact Dr. Reham Abdel-Wahab at raali@mdanderson.org for more information about ICRN clinical trials. Industry Engagement Initiatives (click to enlarge) ©2006-2018 All Rights Reserved, The Cholangiocarcinoma Foundation 5526 West 13400 South, #510, Herriman, Utah 84096, U.S.A. (888) 936-6731 icrn@cholangiocarcinoma.org